Clinical Trial Update: An Open-label Extension Trial of HZNP-HZN-825-301 in Adult Participants With Diffuse Cutaneous Systemic Sclerosis (Diffuse Cutaneous SSc) [Phase 2]

View source ↗

Summary

An open-label extension trial of HZNP-HZN-825-301 in adults with diffuse cutaneous systemic sclerosis was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Cutaneous Systemic Sclerosis
• Systemic Sclerosis

Drugs mentioned

• HZNP-HZN-825-301

Snippet

Sponsor: Amgen | Conditions: Diffuse Cutaneous Systemic Sclerosis, Sclerosis, Systemic | Phase 2 | Status: TERMINATED | Results posted: 2026-01-05